Home LiteratureArticle Details
PMID: 16033645 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.

Respiratory research ·Vol. 6 ·2005-07-20 ·Pages 76

Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, Weidenbach A, Seeger W, Grimminger F

Abstract

Inhaled prostanoids and phosphodiesterase (PDE) inhibitors have been suggested for treatment of severe pulmonary hypertension. In catheterized rabbits with acute pulmonary hypertension induced by continuous infusion of the stable thromboxane analogue U46619, we asked whether sildenafil (PDE1/5/6 inhibitor), motapizone (PDE3 inhibitor) or 8-Methoxymethyl-IBMX (PDE1 inhibitor) synergize with inhaled iloprost. Inhalation of iloprost caused a transient pulmonary artery pressure decline, levelling off within <20 min, without significant changes in blood gases or systemic hemodynamics. Infusion of 8-Methoxymethyl-IBMX, motapizone and sildenafil caused each a dose-dependent decrease in pulmonary artery pressure, with sildenafil possessing the highest efficacy and at the same time selectivity for the pulmonary circulation. When combining a per se ineffective dose of each PDE inhibitor (200 microg/kg x min 8-Methoxymethyl-IBMX, 1 microg/kg x min sildenafil, 5 microg/kg x min motapizone) with subsequent iloprost nebulization, marked amplification of the prostanoid induced pulmonary vasodilatory response was noted and the area under the curve of PPA reduction was nearly threefold increased with all approaches, as compared to sole iloprost administration. Further amplification was achieved with the combination of inhaled iloprost with sildenafil plus motapizone, but not with sildenafil plus 8MM-IBMX. Systemic hemodynamics and gas exchange were not altered for all combinations. We conclude that co-administration of minute systemic doses of selective PDE inhibitors with inhaled iloprost markedly enhances and prolongs the pulmonary vasodilatory response to inhaled iloprost, with maintenance of pulmonary selectivity and ventilation perfusion matching. The prominent effect of sildenafil may be operative via both PDE1 and PDE5, and is further enhanced by co-application of a PDE3 inhibitor.

MeSH Terms
Administration, Inhalation Animals Disease Models, Animal Drug Combinations Drug Synergism Female Hypertension, Pulmonary/diagnosis,drug therapy,physiopathology Iloprost/administration & dosage Lung/blood supply,drug effects,physiopathology Male Phosphodiesterase Inhibitors/administration & dosage Rabbits Treatment Outcome Vasodilation/drug effects
Chemicals
Drug Combinations Phosphodiesterase Inhibitors Iloprost
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schermuly Ralph Theo
Medical Clinic II/V, Justus-Liebig-University Giessen, 35392 Giessen, Germany. ralph.schermuly@innere.med.uni-giessen.de
Inholte Christiane
Ghofrani Hossein Ardeschir
Gall Henning
Weissmann Norbert
Weidenbach Andreas
Seeger Werner
Grimminger Friedrich
References (43)
43 references, click to expand
  1. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
    J Pharmacol Exp Ther. 2000 Feb;292(2):512-20 PMID: 10640287
  2. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
    Am J Respir Crit Care Med. 1999 Sep;160(3):858-65 PMID: 10471609
  3. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.
    J Am Coll Cardiol. 2000 Jan;35(1):176-82 PMID: 10636277
  4. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group.
    Ann Intern Med. 2000 Mar 21;132(6):435-43 PMID: 10733442
  5. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.
    Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3702-7 PMID: 10725373
  6. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
    Anesthesiology. 2000 Jun;92(6):1702-12 PMID: 10839922
  7. Sildenafil in primary pulmonary hypertension.
    N Engl J Med. 2000 Nov 2;343(18):1342 PMID: 11183578
  8. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.
    Biochim Biophys Acta. 2001 May 28;1539(1-2):16-27 PMID: 11389965
  9. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
    Am J Respir Cell Mol Biol. 2001 Aug;25(2):219-25 PMID: 11509332
  10. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
    Circulation. 2001 Sep 11;104(11):1218-22 PMID: 11551870
  11. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
    Circulation. 2001 Nov 6;104(19):2338-43 PMID: 11696475
  12. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation.
    Circ Res. 2002 Feb 8;90(2):151-7 PMID: 11834707
  13. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
    Ann Intern Med. 2002 Apr 2;136(7):515-22 PMID: 11926786
  14. Inhaled iloprost for severe pulmonary hypertension.
    N Engl J Med. 2002 Aug 1;347(5):322-9 PMID: 12151469
  15. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.
    Lancet. 2002 Sep 21;360(9337):895-900 PMID: 12354470
  16. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs.
    J Pharmacol Exp Ther. 2002 Nov;303(2):741-5 PMID: 12388660
  17. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Eur J Med Res. 2002 Oct 29;7(10):435-46 PMID: 12435622
  18. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.
    Am J Respir Crit Care Med. 2003 Apr 15;167(8):1139-41 PMID: 12684251
  19. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
    J Am Coll Cardiol. 2003 Jul 2;42(1):158-64 PMID: 12849677
  20. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    J Am Coll Cardiol. 2004 Oct 6;44(7):1488-96 PMID: 15464333
  21. Biotransformation of the stable prostacyclin analogue, iloprost, in the rat.
    Drug Metab Dispos. 1984 Sep-Oct;12(5):645-51 PMID: 6209077
  22. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
    Ann Intern Med. 1990 Apr 1;112(7):485-91 PMID: 2107780
  23. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.
    Ann Intern Med. 1991 Sep 1;115(5):343-9 PMID: 1863023
  24. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
    Thorax. 1991 Jul;46(7):512-23 PMID: 1877039
  25. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.
    Am J Physiol. 1993 May;264(5 Pt 1):L458-64 PMID: 7684572
  26. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
    Am J Physiol. 1994 May;266(5 Pt 1):L536-43 PMID: 7515580
  27. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Br J Pharmacol. 1994 Oct;113(2):445-50 PMID: 7834194
  28. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families.
    Arch Biochem Biophys. 1995 Sep 10;322(1):1-13 PMID: 7574662
  29. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.
    Physiol Rev. 1995 Oct;75(4):725-48 PMID: 7480160
  30. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.
    J Clin Invest. 1996 Jan 1;97(1):172-9 PMID: 8550830
  31. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    N Engl J Med. 1996 Feb 1;334(5):296-301 PMID: 8532025
  32. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
    Ann Intern Med. 1996 May 1;124(9):820-4 PMID: 8610951
  33. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
    Int J Impot Res. 1996 Jun;8(2):47-52 PMID: 8858389
  34. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange.
    Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):445-53 PMID: 9279222
  35. Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions.
    Adv Second Messenger Phosphoprotein Res. 1997;31:237-51 PMID: 9344255
  36. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.
    J Clin Invest. 1997 Nov 15;100(10):2611-21 PMID: 9366577
  37. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart.
    J Mol Cell Cardiol. 1997 Nov;29(11):3135-46 PMID: 9405187
  38. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
    Am J Respir Crit Care Med. 1998 Feb;157(2):351-70 PMID: 9476844
  39. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message.
    Am J Respir Crit Care Med. 1998 Jul;158(1):279-88 PMID: 9655741
  40. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Am J Cardiol. 1999 Mar 4;83(5A):3C-12C PMID: 10078537
  41. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.
    Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7071-6 PMID: 10359840
  42. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
    Am J Physiol. 1999 Aug;277(2 Pt 1):L225-32 PMID: 10444515
  43. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1500-6 PMID: 10556112
Article Info
Journal
Respiratory research
Abbr.
Respir Res
ISSN
1465-993X
Published
2005-07-20
Epub
2005-00-20
Pages
76
Language
English
Region
England
NLM ID
101090633
PMCID
PMC1180856
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com